Plays Big Boards & Biotechs! Boardmark me as I am an honest, transparent, & well respected investor.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
New Economy Portfolio Update..
Alert..bought $NEOS (7%) at $4.95 & $5.00 as a bouncer play after their recent offering near this level.
Disclaimer: http://bit.ly/OlN9DB
$ARQL..$1.37..continue to keep this on my watchlist. Looking for another re-entry point here soon. Trying to get a better timeline of when the data will be released. Don't want to be in it when it hits because it is such an important binary event for the company it will definitely impact share price big whether positively or negatively.
$TENX..$.88..huge bounce from $.44 after trial failure! Whoa.
$PIOI..$.26..that is huge news there.
Excellent update BioHunter!! Always appreciate your insight into your thoughts on biotech stocks & trends.
Feb2017.. #Biotech watch list.$AVIR $AUPH $CDTX $TRVN $CRBP $LJPC $PTI $RTTR $IDRA $ABEO (Feb data) $ARQL $CTRV $CLRB $MRUS $LXRX-PDUFA $ZSAN $MTNB $IMGN
$AKAO..$IDRA..Wedbush out tonight initiating both $IDRA ($6 PT) and $AKAO ($23 PT) at Outperform from @biotechnova.
@JNVcapital....@biotechnova @abbynach it's not an initiation but an assumption of coverage as the analyst covering them left the firm to join Sofinnova.
$CATB..$1.36..down big time today after their trial in DMD was a big flop. Opened and got as high as $4.05 before the announcement.
http://finance.yahoo.com/news/catabasis-pharmaceuticals-announces-top-line-210100111.html
$SGYP..sold $144M worth of stock today. They played that move from $5.50 to over $7 then sold. At least they gave investors time to lock in some profit along the way.
http://finance.yahoo.com/news/synergy-pharmaceuticals-announces-proposed-public-210100994.html
$TENX..$.46 down 76%; Tenax Therapeutics Announces Top-Line Results From Phase 3 LEVO-CTS Trial in Cardiac Surgery
http://finance.yahoo.com/news/tenax-therapeutics-announces-top-line-140000313.html
New Economy Portfolio & Beginner Portolio Update..
Alert..Closed $IDRA at $1.41 today flat from $1.42 entry (7%)
Alert..Closed $LXRX at $14.30 from $13.65 for a 5% gain. Will re-enter.
Alert..Closed $NTRP at $11.40 from split adjusted $6.65 for a 75% gain.
Beginner Portfolio..
Alert..Closed $ARQL at $1.60 today from $1.40 entry for a 14% gain.
Disclaimer: http://bit.ly/OlN9DB
$BPMX..$.48..Audio DD Post on 1/30/17
http://screencast-o-matic.com/watch/cbVwnHQ9cD
Disclaimer: http://bit.ly/OlN9DB
New Economy Portfolio.. Buying $MRNS at $1.15 & $1.16.
$CBLI..$1.70..Been moving well here the past few trading days. On watch here! Old PR here w/ some relevant timelines to watch for.
BUFFALO, NY--(Marketwired - Nov 14, 2016) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the third quarter ended September 30, 2016.
Cleveland BioLabs reported net income of $1.1 million, excluding minority interests, for the third quarter of 2016, or $0.10 per share, compared to a net loss, excluding minority interests, of $(3.1) million, or $(0.31) per share, for the same period in 2015. Net loss, excluding minority interests, for the first nine months of 2016 was $(1.4) million, or $(0.13) per share, compared to a net loss, excluding minority interests, of $(11.2) million, or $(1.93) per share, for the same period in 2015. The reduction in net loss for both periods due to operating results was attributable to increased revenues and lower costs with the most significant being a reduction in the non-cash adjustment to our warrant liabilities and reduced operating costs aligned with our streamlined focus primarily on pursuing a pre Emergency Use Authorization ("pre-EUA") for entolimod with the U.S. Food and Drug Administration ("FDA"). Additionally, the weighted average outstanding shares for the nine month period significantly increased, which thereby lowers the per share results, due to the issuance of approximately 6.5 million shares in July 2015.
As of September 30, 2016, the Company had $14.9 million in cash, cash equivalents and short-term investments, which, based on the Company's current operational plan, is expected to fund the Company's operating requirements beyond one year.
Yakov Kogan, Ph.D., MBA, Chief Executive Officer, stated, "The side-by-side analytical comparability analysis of two formulations of entolimod is on schedule to be completed in the fourth quarter of 2016. Once we have this data and once the FDA has finalized the biocomparability study design, the biocomparability study in non-human primates ("NHP") may commence. We expect the NHP study will require approximately 6 months to complete, and we will update guidance on this point after the FDA has completed its reviews and our vendors have confirmed timing."
"In addition, we are in ongoing discussions with the European Medicines Agency ("EMA") for a pediatric investigational plan ("PIP") for entolimod as a medical radiation countermeasure. A proposed PIP was filed with the EMA. The EMA requires an agreement on a PIP with the sponsor as a prerequisite to filing a Marketing Authorization Application ("MAA"). We cannot currently estimate when an agreement on the PIP will be reached or if any additional studies will be required for an MAA submission."
"Clinical oncology studies with entolimod, CBLB612 and Mobilan are progressing in the Russian Federation," added Dr. Kogan. "Recruitment was completed in a Phase 2 study of entolimod as a neo-adjuvant therapy in treatment-naïve patients with primary colorectal cancer and a Phase 2 study of CBLB612 as myelosuppressive prophylaxis in patients with breast cancer receiving doxorubicin-cyclophosphamide chemotherapy. The data from these studies are being analyzed. Panacela Labs is now dosing Mobilan in two dose-escalation Phase 1 studies evaluating single and double injection regimens administered directly into the prostate of patients with prostate cancer. All of these studies are supported by development contracts with the Russian Federation Ministry of Industry and Trade."
$MRNS..$1.27..Key Catalysts! Thx Kei for the heads up.
Near-term Clinical Value Catalysts ·
Initiate Phase 2 study in women with postpartum depression (PPD) in 1H 2017 ·
Initiate Phase 2 study in patients with refractory status epilepticus (RSE) in 1H 2017 ·
Report top-line data from patients with orphan, genetic disorders in mid-2017 ·
Report data from PPD patients in 2H 2017 ·
Report data from RSE patients in 2H 2017
http://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=11773218
Third Quarter Financial Update At September 30, 2016, the Company had cash, cash equivalents and investments of $37.1 million, compared to $57.7 million at December 31, 2015. The Company believes that its cash, cash equivalents and investments, as of September 30, 2016, are adequate to fund operations into the second half of 2018.
The number of outstanding shares of the registrant’s common stock, par value $0.001 per share, as of November 7, 2016 was: 19,705,495.
$NEOT..$1.44..Q2 Key Clinical Trial Data..
http://investors.neothetics.com/phoenix.zhtml?c=253672&p=irol-newsArticle&ID=2231576
New Economy Portfolio Update..Alert..bought a stock that has a chance to go higher in the short-term.
Alert..bought $ZSAN..$1.11..6% position as the company has key data release in late February. This one could be a nice mover into data. Only 10min left in the trading day. 140K shares traded.
Disclaimer:..http://bit.ly/OlN9DB
$BPMX..$.45..Volume before price here. This will move as their catalyst is very solid. We know it will be here in Mid-April.
New Economy Portfolio Update..Alert..bought three stocks that are moving today and have a chance to go higher in the short-term.
Alert..bought $IDRA..$1.42..7% position as the company has key data that is going to be presented in Feb at the SITC-ASCO symposium for IMO-2125.
Alert..bought $SGYP..$5.50..6% position as the company is still being looked at as a takeout target. I have heard Orbimed mention that now that the drug has been approved that it has been somewhat derisked.
Alert..bought $IMGN..$2.43..7% position as the company will be presenting data in March (12-15) at the SGO Meeting. I think the company will move higher off of this presenation.
Disclaimer:..http://bit.ly/OlN9DB